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Abstract
Tumor-initiating cells (T-ICs) discovered in various tumors have been widely reported. However, T-IC populations in salivary
gland tumors have yet to be elucidated. Using the established Pleomorphic Adenoma Gene-1 (Plag1) transgenic mouse
model of a salivary gland tumor, we identified CD44
high (CD44
hi) tumor cells, characterized by high levels of CD44 cell
surface expression, as the T-ICs for pleomorphic adenomas. These CD44
hi tumor cells incorporated 5-bromo-2-deoxyuridine
(BrdU), at a lower rate than their CD44
negative (CD44
neg) counterparts, and also retained BrdU for a long period of time. Cell
surface maker analysis revealed that 25% of the CD44
hi tumor cells co-express other cancer stem cell markers such as CD133
and CD117. As few as 500 CD44
hi tumor cells were sufficient to initiate pleomorphic adenomas in one third of the wildtype
mice, whereas more than 1610
4 CD44
neg cells were needed for the same purpose. In NIH 3T3 cells, Plag1 was capable of
activating the gene transcription of Egr1, a known upregulator for CD44. Furthermore, deletion of sequence 81–96 in the
Egr1 promoter region abolished the effect of Plag1 on Egr1 upregulation. Our results establish the existence of T-ICs in
murine salivary gland tumors, and suggest a potential molecular mechanism for CD44 upregulation.
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Introduction
Tumors comprise of a heterogeneous population of cells with
varying morphologies and functions. It has been proposed that
tumors may not be mere monoclonal expansions of cells. Instead,
they may be sustained by a specialized type of tumor-initiating
cells (T-ICs), also known as cancer stem cells, which are capable of
self-renewal and aberrant differentiation [1]. Many tumors have a
hierarchical organization of T-ICs, rapidly dividing cells and
differentiated tumor cells. These T-ICs are not only a renewable
source of tumor cells, but are also a source of tumor resistance,
leading to tumor progression, metastasis and recurrence [2–4].
Hence, identifying these cells and their respective cell surface
markers are crucial to the understanding of the mechanisms that
govern cancers, thereby leading to the development of better and
more strategic oncological therapies.
Early experimental evidence for T-ICs came from human acute
myeloid leukemia studies. Human CD34
+CD38
2 acute myeloid
leukemia cells were capable of initiating leukemia when transplant-
ed in non-obese diabetic mice with severe combined immunode-
ficiency (NOD/SCID mice) [5]. More recently, T-ICs were
identified and isolated from epithelial tumors such as breast tumors
[6–8], glioblastomas [9–10] and colorectal carcinomas [11], where
each of these tissue-specific T-ICs displayed distinct cell surface
markers.Forinstance,thosediscoveredinhumanbreasttumorshad
a subpopulation of CD44
+CD24
2/low tumor cells, capable of
initiating and sustaining tumor growth after they were xenografted
into NOD/SCID mice. These CD44
+CD24
2/low cells contained
mixed populations of epithelial tumor cells, and often phenocopied
the histological heterogeneity of their parent tumors [8]. Another
example of T-ICs includes the CD133
+ tumor cells discovered in
glioblastoma multiforme and medulloblastomas of the human
brain, where CD133
+ subpopulations accounted for 5–30% of the
total number of tumor cells. These cells were found to be tumo-
rigenic and could reproduce the phenotypic diversity and differen-
tiation pattern of the parent tumors when injected intracerebrally
[12]. In human colorectal cancer, the ability to engraft in vivo in
NOD/SCID mice is restricted to EpCAM
high/CD44
+ tumor cells.
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high/CD44
+ cells also maintained
a differentiated phenotype and reproduced the phenotypic
heterogeneity of their parental lesions [13].
Pleomorphic adenomas are benign tumors found in salivary
glands. They are the most common of all salivary gland tumors,
and can account for up to 80% of all parotid neoplasms. While
most human pleomorphic adenomas are benign and can be easily
treated via various forms of curative resections, some of them may
recur decades after removing the primary tumor. An even smaller
percentage of them can become malignant (carcinoma ex-
pleomorphic adenoma) with metastasis to distant and remote sites
[14–15]. Investigations on the tumorigenesis of pleomorphic
adenomas revealed that the oncogenic activation of Pleomorphic
Adenoma Gene 1 (Plag1) played a pivotal role in their
development within salivary glands. Various studies including
ours verified that Plag1 transgenic mice spontaneously developed
salivary gland tumors with similar histopathological features to
human pleomorphic adenomas [16–18]. Using this model, we
sought to establish the presence of T-ICs and identify the
corresponding cell surface markers for T-IC isolation. In this
study, we provided evidence that CD44
hi cells function as the T-
ICs in pleomorphic adenomas.
Results
CD44 protein expression in normal salivary gland or
salivary gland tumor cells
Both normal salivary gland and tumor salivary gland cells
displayed CD44 staining via FACS analysis. The mean fluorescent
intensities (MFI) for CD44 was significantly higher on tumor cells
than on wildtype cells (84 vs. 7, p,0.05) (Figure 1a, b). We further
characterized the CD44 cells into CD44
hi, CD44
intermediate
(CD44
int) and CD44
neg subpopulation by MFI. We noted that
the CD44
hi population registered MFI that was one log higher
than that of the CD44
neg population. The percentage of CD44
hi
cells in the total salivary gland tumor cell population was 8.6%.
This was significantly higher than the percentage of CD44
hi cells
in the wildtype salivary glands (0.6%) (Figure 1c). Thus, CD44
protein expression was significantly upregulated in salivary gland
tumor cells.
Phenotype of CD44
hi tumor cells
CD133 and CD117 are two markers frequently associated with
T-ICs [7,10,19–21]. We examined their expression in different
CD44 subpopulations of tumor cells by flow cytometry. CD44
hi
subpopulation contained cells which co-stained with CD117 and
CD133 antibodies. These cells constituted about 25% of the total
CD44
hi cells. In contrast, only 6% of CD44
int cells stained for
CD117 and CD133, and less than 0.5% of the CD44
neg cells
expressing CD117 and CD133 (Figure 2a).
Many studies have revealed that T-ICs do not divide as fast as
their non-T-IC counterparts [22–24]. To determine if this was the
case in salivary gland tumors, we compared the cell cycling rate
and label retaining ability of CD44
hi and CD44
neg tumor cells
(Figure 2b). After a 5-day pulse of BrdU, about 3.5% CD44
hi cells
incorporated BrdU, compared to 19% of CD44
neg cells, indicating
that CD44
hi cells were slow-cycling compared to CD44
neg cells.
When the second group of mice was similarly pulsed with BrdU
for 5 days, followed by a rest period of 4 weeks, about 3% CD44
hi
cells were still BrdU positive, whereas only about 5% of CD44
neg
cells retained BrdU marker. Therefore, majority of CD44
hi cells
retained their BrdU over the course of 4 weeks whereas only a
small fraction of CD44
neg cells were able to do so. The slow
baseline cycling rate and robust BrdU retaining ability of CD44
hi
cells were consistent with stem cell like properties [22–24].
Transcription factors such as Oct-4, Nanog, Sox2 and
telomerase are implicated in linage commitment or maintenance,
and function for cells of stem cell-like properties [25–29]. We
performed realtime PCR to assess gene transcript levels for Oct4,
Nanog, and Sox2, as well as mouse telomerase reverse
transcriptase (mTRET), a catalytic subunit of telomerase, in
CD44
hi and CD44
neg tumor cells. Transcript levels for those stem
cell related factor were higher in CD44
hi cells than in CD44
neg
cells (Figure 2c).
High tumorigenicity of CD44
hi tumor cells in vivo
We have demonstrated with Plag1 transgenic mouse model that
pleomorphic adenomas contained a population of CD44
hi cells
that co-express other common T-ICs markers and propagate in
slow-cycling state, and have upregulated stem cell related
transcription factors. To determine if these CD44
hi cells could
induce tumors in mice, in vivo tumorigenic experiments were
performed. For all our in vivo transfer experiments, immunocom-
petent wildtype CD57/BL6 mice instead of immunocomprised
NOD/SCID mice were used as hosts [30].
The pleomorphic adenoma tumor cells were sorted into various
populations according to their surface markers. Comparable cell
populations were injected into bilateral salivary glands of the same
mouse. Unsorted 1610
5 tumor cells initiated tumors in about two
thirds of the recipients, and 1610
4 unsorted tumor cells generated
tumors in less than one third of the recipients. In contrast, as few
as 1610
3 sorted CD44
hi tumor cells gave rise to tumors in a
majority of recipients (7/9); 5610
2 sorted CD44
hi tumor cells
generated tumors in one third of the recipients. For CD44
neg
tumor cells, 1610
5 cells gave rise to tumors in more than half of
recipients (5/9); 1610
4 tumor cells gave rise to tumor in one
eighth of the recipients. CD44
hi cells showed 10–20 fold greater
ability to initiate tumors in wildtype mice compared with the total
number of tumor cells (Table 1), suggesting that the CD44
hi
population was enriched for T-ICs.
We next asked whether CD117 and CD133 can be used as T-
ICs markers in our tumor model. When CD44
negCD117
+CD133
+
tumor cells were transplanted at the dose of 1610
4 cells, two out of
eight recipients developed a secondary tumor. However, when
CD44
hiCD117
+ CD133
+ triple marker positive tumor cells were
sorted and transplanted into the recipients, these cells initiated
secondary tumors in one third of the recipients at the dose of
2610
2 cells. Thus, T-ICs of pleomorphic adenomas were further
enriched in CD44
hiCD117
+CD133
+ populations, but not
CD44
negCD117
+CD133
+ populations.
Tumors initiated by CD44
hi or CD44
hiCD117
+CD133
+ cells
shared similar histological features with the primary tumors
(Figure 3a–c). They often form luminal or cyst-like structures, and
also contained myoepithelial cells in a disordered pattern. CD44
expression was similar (6–10%) in both the primary and secondary
tumors initiated by CD44
hi or CD44
hiCD117
+CD133
+ cells
transplants (Figure 3a–d). Mean fluorescent intensity analysis of
CD44 revealed that all three groups of tumors expressed similar
levels of CD44 (Figure 3e). Secondary tumors initiated by CD44
hi
or CD44
hiCD117
+CD133
+cells predominantly contained
CD44
neg cells. Therefore, CD44
hi tumor cells were able to
produce secondary tumors that resemble primary tumors,
consisting of both CD44
hi and CD44
neg cells.
Plag1 upregulates Egr1 transcription
Egr1, Early Growth Response 1, a positive regulator of CD44
[31–32], was found to be significantly upregulated in Plag1
T-IC in Murine Salivary Gland Tumor
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and Egr1 gene transcript levels were assessed by realtime
quantitative PCR with cDNA extracted from CD44
hi and
CD44
neg tumor cells. Both Plag1 transcripts and Egr1 transcripts
levels were significantly higher in CD44
hi cells than in CD44
neg
cells (Figure 4a).
Egr1 promoter sequence analysis revealed 4 putative Plag1
binding consensus sites (Figure 4b). Co-transfection of Plag1
expression vector (pCI-neo-Plag1) and mouse Egr1 reporter
construct containing all four binding sequences induced robust
luciferase activity. This data indicated that Plag1 could serve as a
positive regulator for Egr1 transcription. To identify the promoter
region important for Plag1-mediated upregulation of Egr1,
truncated forms of Egr1 promoters were constructed to contain
only 3 out of 4 putative binding sequences (Figure 4b). Deleting
the binding sequences in Egr1 promoter region 2750–2735 or
2301–2287 did not dampen the effects of Plag1 on Egr1
upregulation. However, when the Egr1 promoter sequence in
region 81–96 was deleted, upregulation of Egr1 induced by Plag1
was almost completely abolished (Figure 4c). These results
demonstrated that promoter sequences 81–96 were necessary for
Plag1-mediated Egr1 upregulation.
Discussion
A majority of T-IC studies employ human tumor xenotransplants
thatutilizeimmunocompromised micewithout a functionaladaptive
immunesystem (Tand B lymphocytes)astherecipientsof human T-
ICs [33]. However, these mice still harbor a functioning innate
immune system which could cause cellular ‘graft’ rejection. Immune
rejection of transplanted T-ICs would result in an inaccurate
assessment of the frequency of T-ICs in tumors [30,34]. A recent
study by Quintana et al. highlighted the impact of immune rejection
on T-IC frequency estimations [29]. Using a NOD/SCID mice
Figure 1. Frequency of CD44
hi cells in mouse salivary gland tumors. (a) Histograms of CD44 staining in normal salivary gland cells from
wildtype mice (left panel) or tumor salivary gland cells from Plag1 transgenic mice (right panel). Representative graphs from of each group (n=7) are
shown. (b) CD44 mean fluorescent intensity in normal salivary gland cells from wildtype mice (left panel) or tumor salivary gland cells from Plag1
transgenic mice. n=9, * p,0.05 (normal, vs. tumor, t-test); (c) Percentage of CD44
hi cells among total salivary gland cells in normal glands or tumor
glands. n=9, * p,0.05 (normal, vs. tumor, t-test).
doi:10.1371/journal.pone.0023282.g001
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IL2g
2/2), they showed that human melanoma cells initiated tumors
100% of the time upon transplantation into NOD/SCID IL2g
2/2
hosts. However, with conventional NOD/SCID recipients, the
frequency of tumor-initiating cells was found to be about 0.1% [34].
Intrinsic differences among various immunodeficient mouse strains
could account for the T-IC frequency variability, and such
discrepancies could greatly confound the interpretation of experi-
mental data. Therefore, assessing the efficacy of T-IC models in
syngeneic transplantation systems is a critical and imperative step
that formed the foundation and basis of our testing T-ICs in
syngeneic, immunocompetent hosts.
We found that salivary gland tumors induced by Plag1
overexpression contained CD44
hi cells that incorporated BrdU
at a low cycle rate and retained BrdU better than CD44
neg cells;
and that CD44
hi cells have higher levels of transcripts of stem cell
related genes, Oct-4, Nanog, Sox2 and telomerase. These data
collectively suggest a stem cell-like phenotype for CD44
hi tumor
cells. A few hundred transplanted tumor cells were able to initiate
new tumors in syngeneic recipients. Secondary tumors shared the
same histopathological features and cellular composition as their
parent tumors. These findings supported previous reports that
identified CD44 as a stem cell marker in colon, prostate cancer,
breast, and head and neck squamous cell carcinomas [22,35–37].
These studies and our results (Figure 1) indicated that CD44
expression was widely distributed across a number of tumors and a
range of CD44 expression levels—negative to very high levels—
were observed in the tumor cells. This broad pattern of CD44
Figure 2. Phenotypic analysis of tumor cells. (a) CD117 and CD133 staining of tumor cells. Mice salivary gland tumor cells were divided into
CD44
neg, CD44
int, and CD44
hi subpopulations via FACS; each subpopulation was analyzed for CD117 and CD133 expression. (b) BrdU incorporation.
BrdU was injected into tumor-bearing mice at 50 mg/kg twice daily for 5 days, then half of the mice were sacrificed and half were rested for 4 weeks
before CD44 and BrdU analysis. (n=5 each group, * p,0.05 t-test). (c) Comparison of transcript levels for stem cell related genes in CD44
neg and
CD44
hi tumor cells. Transcripts levels for all four genes were higher in CD44
hi cells than in CD44
neg cells (p,0.05, t-test).
doi:10.1371/journal.pone.0023282.g002
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analyses of CD44
+ tumor populations. Hence, Chu et al.
categorized tumor cells into CD44
hi and CD44
neg populations
[22], where CD44
hi populations were defined by cells exhibiting a
mean fluorescent intensity (MFI) of at least half a log higher than
CD44
neg cells. In this study, we defined CD44
hi cells as exhibiting
MFI that was one log higher than that of CD44
neg cells. This is a
more stringent criterion. Our results revealed that in murine
salivary gland tumor, CD44
hi population was enriched for T-ICs
as well.
CD113 is a marker expressed on hematopoietic stem cells
isolated from cord blood. The use of CD133 as a T-IC marker is
still debatable, largely due to the variability in its tissue-specific
expressions. For example, in a colon adenocarcinoma xenotrans-
plant model, CD133
+ cells did not display increased tumorigenic-
ity [22] even though they have been reportedly found in T-ICs
[38]. The intrinsic difference among these tumor models could
contribute to this discrepancy. CD117, a cytokine receptor
Table 1. Tumorigenicity of tumor cell subpopulations in vivo.
number of cells transferred
cell type 1610
6 1610
5 1610
4 1610
3 5610
2 2610
2
Unsorted cell 8/8 6/9 2/9 0/9 0/9 0/9
CD44
hi 7/7 9/9 8/8 7/9 3/9 0/9
CD44
neg 8/8 5/9 1/8 0/9 0/9 0/9
CD44
hiCD133
+CD117
+ 4/4 5/5 8/8 9/9 6/9 3/9
CD44
negCD133
+CD117
+ 3/7 2/8 1/9 0/9 0/9
Subpopulations of tumor cells were sorted with markers as indicated and
transferred at indicated doses to wildtype mice recipients. Recipients were
monitored up to 3 months after transfer for tumor formation. Unsorted tumor
cells were used as control. (numbers in the table: tumor bearing mice/injected
mice).
doi:10.1371/journal.pone.0023282.t001
Figure 3. Histological and cell surface marker analysis for secondary tumors. (a–c) Each panel includes a picture of tumor bearing mouse
(top), H&E staining (4006) of the tumor (middle), and tumor cell CD44 staining detected by FACS (bottom). (a) Primary tumors from Plag1 transgenic
mice. Mice developed bilateral salivary gland tumors. (b) Tumors derived from CD44
hi tumor cell transplant. Mice were injected with 1610
3 CD44
hi
cells at left side and 1610
3 CD44
neg cells at right side as control. Tumors only developed on the left side of the recipients. (c) Tumors derived from
CD44
hiCD117
+CD133
+ tumor cells transplant. Mice were injected with 1610
3CD44
hiCD117
+CD133
+ c e l l sa tl e f ts i d ea n d1 610
3
CD44
negCD117
+CD133
+ cells at right side as control. Tumors only developed at left side of the recipients. (d) Percentage of CD44
hi cells among
total cells in primary tumors (open bar), among total cells in tumors derived from CD44
hi cells (grey-color filled bar), and among total cells in tumors
derived from CD44
hi CD117
+CD133
+ cells (shaded bar) (n=9, P.0.05 between any two groups). (e) CD44 mean fluorescent intensity in primary
tumors (open bar), in tumors derived from CD44
hi cells (grey-color filled bar), and in tumors derived from CD44
hi CD117
+CD133
+ cells (shaded bar)
(n=9, P.0.05 between any two groups).
doi:10.1371/journal.pone.0023282.g003
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been detected on the surfaces of various tumors stem cells,
including those found in leukemia and lung cancer [20–21]. Our
study showed higher CD133 and CD117 expression levels in
tandem with CD44
hi cells, when compared with the CD44
neg
population. Triple marker CD44
hiCD133
+ CD117
+ cells pos-
sessed potent tumor initiating capacities, indicating that CD44
hi
CD133
+ CD117
+ could be used as a robust marker for T-IC
identification in salivary gland tumors.
Although CD44
+ markers have been widely used to isolate and
identify T-ICs, it was not until recent that the functional roles of
CD44 in T-ICs were investigated [11]. Du et al. used RNA
interference to knockdown CD44 and CD133 in colorectal T-ICs
isolated from patients. They showed that the deletion of CD44,
and not CD133, strongly prevented clonal formation and inhibited
the tumorigenicity of T-ICs in a xenografted model [11].
Therefore, the authors deduced that CD44 not only functioned
as a marker for T-ICs, it could also participate in tumorigenic
signaling pathways.
Our data showed that both Plag1and Egr1 gene transcriptions
were upregulated in murine salivary gland CD44
hi tumor cells
compared to CD44
neg cells (Figure 4a). We also demonstrated that
Plag1 activated Egr1 gene transcription, and Egr1 promoter
region 81–96 was necessary in mediating this process (Figure 4c).
The CD44 gene contains an Egr1 binding site at 2301 in the
promoter region, and this Egr1 binding motif is indispensable to
Figure 4. Plag1 upregulated Egr1 transcription in NIH3T3 cells. (a) Plag1 and Egr1 transcripts levels in CD44
hi and CD44
neg tumor cells were
determined by real-time PCR. Expression levels were normalized to Ppib gene as internal control (* p,0.05). (b) Schematic diagram of Egr1 promoter
region and truncated forms used. Four putative Plag1 binding sequences are marked in the mouse Egr1 promoter region 2750 to 132. Egr-Full-luc
contains all four sequences, Egr-D1-luc lacked binding sequence in region 2750–2735, Egr-D2-luc lacked binding sequence in region 2301–2287,
Egr-D3-luc lacked binding sequence in region 81–96. (c) Transactivation of Egr1 promoter by Plag1. Co-transfection of vector pCI-neo-Plag1 and
luciferase reporter driven by truncated forms of Egr1 promoter in NIH3T3 cells. As expected, pCI-neo empty vector co-transfected with Full-luc did
not induce significant luciferase activity. Relative luciferase activity was normalized with b-galactosidase activity derived from pSV-b-galactosidase
control vector. Results were shown as average of triplicates.
doi:10.1371/journal.pone.0023282.g004
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collectively indicate a plausible Plag1-Egr1-CD44 regulatory
pathway in the T-ICs of pleomorphic adenomas.
Conclusion
Our study demonstrated that CD44
hi cells function as the T-ICs
in pleomorphic adenomas that are capable of generating
secondary tumors with similar histopathological features to the
parent tumors. In addition, we provided evidence that Plag1 was
capable of activating gene transcription of Egr1, an established
upregulator for CD44, suggesting that Plag1 may be potentially
involved in upregulation of CD44.
Materials and Methods
MMTV-PLAG1 transgenic mice
Mouse mammary tumor virus (MMTV)-PLAG1 transgenic
mice, maintained in C57BL/6 background were generated at
Experimental Animal Center, Department of Medical Genetics,
Shanghai Jiaotong University School of Medicine [17–18]. All
transgenic mice used in this study were genotyped via PCR, and
were all heterozygous for the Plag1 transgene. Almost all the
transgenic mice developed submandibular gland pleomorphic
adenomas between 4–12 weeks old. Age (6–8 weeks old) and sex-
matched C57BL/6 wildtype mice were used as controls. All the
procedures described were approved by the Animal Use and Care
Committee of Shanghai Jiaotong University School of Medicine
(approval number: SYKX-2008-0050).
Preparation of single cell suspensions from salivary gland
tumors and normal salivary gland tissues
To generate single cell suspensions from salivary gland tumors,
tumor samples from Plag1 transgenic mice were minced with
scissors, mixed with 0.25% trypsin-EDTA and incubated at 37uC
for 1 hour in a shaking water bath. Following incubation, cells
were collected after blocking with PBS containing 10% FBS
(Gibco, Carlsbad, CA, USA) and serially filtered through 200 and
100 mm nylon meshes. Contaminated red blood cells were
removed by osmotic lysis and the filtered cells were suspended
in PBS/1%FBS. Similarly, normal salivary gland tissues from
C57BL/6 wildtype mice were also prepared into single cell
suspensions.
Flow cytometry
The antibodies used in the study included immunoglobulins,
anti-CD44 allophycocyanin (APC), anti-CD133 phycoerythrin
(PE), anti-CD117 fluorescein isothiocyanate (FITC) and anti-BrdU
(FITC) (eBioscience, San Diego, CA, USA). Via-probe 7- Amino-
actinomycin D (BD, San Jose, CA, USA) was used to gate live
cells.
For cell surface staining, cells were counted and transferred to a
15-ml tube before they were washed and re-suspended. To
minimize the unspecific binding of antibodies, cells were first
incubated with mouse immunoglobulins at 0.06–0.1 mg/1610
6
cells on ice for 10 minutes, after which the samples were washed
twice. Fluorescent-conjugated antibodies were then mixed with the
re-suspended cells, incubated for another 30 minutes on ice and
washed twice again.
To label the cells and investigate their BrdU retaining abilities,
the mice were injected with BrdU at 50 mg/kg twice daily for 5
days. They were then divided into two groups, where one was
sacrificed immediately and the other group was left alone for 4
weeks. Cell surface staining was then performed on the single cell
suspensions before being permeablized with 1% PFA and 0.5%
Tween-20 in PBS for 30 minutes at room temperature. This was
followed by DNaseI treatment at 100 U/ml (Sigma, St Louis,
MO, USA) in a 37uC water bath for 15 minutes. Anti-BrdU
antibodies were then added into cells for 45 minutes at room
temperature. FACS Caliber (BD, San Jose, CA, USA) was used for
cell acquisition and CellQuest (BD, San Jose, CA, USA) was used
for analysis. For all analyses, live cells were gated based on 7-AAD
negative staining.
Cell sorting and tumorigenicity experiments
Cell sorting was performed using a BD FACSAria cell sorter.
Sorted cells were spun down by low speed centrifuga-
tion(1000 rpm for 5 min) and re-suspended in RPMI 1640
supplemented with 10% FBS, 20 mM Hepes and 2 mM L-
glutamine. In all the experiments, a small aliquot of cells was set
aside to confirm cell counts and viability. Once confirmed, cells
were diluted to appropriate injection doses and injected into
murine submandibular glands with 28G needles and microliter
syringes (Hamilton, Reno, NV, USA) under anesthesia. To
minimize experimental variability, comparative groups of cells
were injected into the contralateral submandibular glands of the
same animal. The injected mice were followed up intensively for
the subsequent 3 months.
Realtime PCR
RNA from salivary gland tissues and tumor tissues were
extracted with TRIzol (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. RNA samples were subse-
quently treated with DNase I (Invitrogen, Carlsbad, CA, USA)
twice to avoid DNA contamination, followed by reverse-
transcription into cDNAs using AMV reverse transcriptase
(TaKaRa, Shiga, Japan). Primers for realtime PCR on cDNA
samples were: Plag1: GTTTCTAAGTACAAATTAC; CATGT-
GTATGGAGGTGATT; Egr1: GAGCGAACAACCCTATGA-
GC; AGGCAGAGGAAGACGATGAA; Oct4: GAGGAGTCC-
CAGGACATGAA; TGGTCTCCAGACTCCACCTC; Nanog:
AAGTACCTCAGCCTCCAGCA; GCTTGCACTTCATCCT-
TTGG; Sox2: ATGATGGAGACGGAGCTGAA; TTGCTGA-
TCTCCGAGTTGTG; mTERT: GGATTGCCACTGGCTC-
CG; TGCCTGACCTCCTCTTGTGAC; Primers for PPib
(internal control) include: TCGTCTTTGGACTCTTTGGAA;
TCCTTGATGACACGATGGAA.
Transfection and reporter gene assays
NIH3T3 cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum (Gibco,
Carlsbad, CA, USA), 50 U/mL streptomycin and 4 mM l-
glutamine. The NIH3T3 cells were then transfected with plasmid
DNA using FuGENE 6 (Roche, Indianapolis, IN, USA). Mouse
(2957 to 132) Egr1 promoter fragments were cloned into pGL3-
basic (Promega, Madison, Wisconsin, USA) and named Egr-Full-
luc. For deletional studies, Egr1 promoter fragment 2470–132
was cloned into pGL3-basic and named Egr-D1-luc; fragment
2148–132 was cloned into pGL3-basic and named Egr-D2-luc;
fragment 2148–64 was cloned into pGL3-basic and named Egr-
D3-luc. Plag1 gene expression vector pCI-neo-Plag1 and empty
pCI-neo vector were co-transfected into NIH3T3 cells in triplicate
on 48-well plates with an Egr-luc reporter construct (Egr-Full-luc
or Egr-D1-luc or Egr-D2-luc or Egr-D3-luc). Luciferase activity
was measured 48 hr after transfection with luciferase assay system
(Promega, Madison, Wisconsin, USA) according to the manufac-
turer’s instruction. Relative luciferase activity was normalized with
b-galactosidase activity derived from pSV-b-galactosidase control
vector (Promega, Madison, Wisconsin, USA).
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